SCHEMBL1660701

SCHEMBL1660701

Fc1cc(I)ccc1CBr

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.33
AKR1B1 P15121 1/20 0.33
AGXT P21549 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30028529 1.00 IDO1 (0.33) IDO1AKR1B1AGXT
SCHEMBL1131149 0.82
SCHEMBL566305 0.78 IDO1 (0.36) IDO1
SCHEMBL10487847 0.77 LOXL2 (0.42) IDO1AKR1B1AGXT
SCHEMBL15012263 0.77 SLC6A4 (0.37) IDO1AKR1B1AGXT
SCHEMBL26586522 0.77 IDO1 (0.33) IDO1AKR1B1AGXT
SCHEMBL16589342 0.77 IDO1 (0.33) IDO1AKR1B1AGXT
SCHEMBL30028568 0.77 SLC6A4 (0.37) IDO1AKR1B1AGXT
SCHEMBL257063 0.77 AKR1B1 (0.35) IDO1AKR1B1AGXT
SCHEMBL120150 0.76 IDO1 (0.54) IDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271674-B9 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-03-11 EP disclosed
US-12570642-B2 GLP-IR modulating compounds GILEAD SCIENCES, INC. (US) 2026-03-10 US disclosed
EP-4691554-A2 GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
EP-4271674-B3 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 EP disclosed
EP-4271672-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 EP disclosed
US-20250312352-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-10-09 US disclosed
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
EP-4520393-A2 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-03-12 EP disclosed
EP-4271674-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-02-12 EP disclosed
US-5596006-A ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1997-01-21 US disclosed
EP-0711162-A4 IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS DU PONT MERCK PHARMA (US) 1996-09-04 EP disclosed
US-5545651-A HYPOTENSIVE AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-08-13 US disclosed
EP-0711162-A1 IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-15 EP disclosed
US-5395844-A Hypotensive agents; congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-03-07 US disclosed
WO-1994028896-A1 IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-12-22 WO disclosed
CN-1092068-A The pyridone biphenyl that alkoxy methyl replaces BAYER AG (DE) 1994-09-14 CN disclosed
CN-1089260-A Trisubstituted biphenyls BAYER AG (DE) 1994-07-13 CN disclosed
EP-0594019-A1 Trisubstituted biphenyl as angiotensin II antagonistes BAYER AG (DE) 1994-04-27 EP disclosed
EP-0594022-A1 Alkoxymethyl substituted pyridinone-biphenyls as angiotensin II antagonists BAYER AG (DE) 1994-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312352-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 IDO1 4145/4885AKR1B1 2682/4885AGXT 2799/4885
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR IDO1 2577/4885AKR1B1 2435/4885AGXT 2300/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 IDO1 805/4885AKR1B1 599/4885AGXT 686/4885
US-12570642-B2 GLP-IR modulating compounds GLP1R, GIPR, GPR119 IDO1 2279/4885AKR1B1 1692/4885AGXT 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.